Industry | Biopharmaceutical Pharmaceutical |
---|---|
Founded | October 14, 1994 |
Headquarters | 440 Boul. Armand-Frappier Suite 300, Laval, Québec , |
Website | prometic |
Prometic Life Sciences Inc. is a Canada publicly traded biopharmaceutical company.
Prometic was founded in 1988, as a commercial spinoff of research at the University of Cambridge on affinity chromatography.[1] Its founder was the current President and CEO, Pierre Laurin, whose research formed the basis for the company's products.[1] On May 19, 1998,the Corporation went public through a listing on the Toronto Stock Exchange.
In August 2016, the company announced the acquisition of Telesta Therapeutics.[2]
Most of the company's products are based on its affinity chromatography process. One use of this process is the purification of drugs, reducing impurities and thus side effects.[1] A second use is removing pathogens from human blood; in 2002, ProMetic formed a joint venture with the American Red Cross to remove pathogens and viruses from collected blood.[3] A third application is to extract and purify therapeutic proteins from human plasma, which are then used in the creation of therapeutics and orphan drugs.
Prometic has two business segments: the protein technologies segment and the small-molecule therapeutics segment.
The small-molecule therapeutics segment produces products for sufferers of fibrosis, cancer and autoimmune diseases. The company most prominent product is PBI-4050, an anti-fibrosis product. [4]
Headquartered in Laval, Quebec, Prometic has:
It also conducts business development activities in the US, Europe and Asia. As of 2015, it has approximately 250 employees.